Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
2018 · EBioMedicine · 77 citations
https://doi.org/10.1016/j.ebiom.2018.02.001
I
Ilaria Attili
Ripamonti(IT)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
129
Papers
2.2K
Citations
27
h-index
46
i10-index
Ilaria Attili is an academic researcher from Ripamonti. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 27, co-authored 110 publications.
ORCID: 0000-0003-1333-6622Papers by this author
worksEarly assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
2020 · British Journal of Cancer · 41 citations
https://doi.org/10.1038/s41416-020-0833-7
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
2021 · ESMO Open · 40 citations
https://doi.org/10.1016/j.esmoop.2021.100355
erbB in NSCLC as a molecular target: current evidences and future directions
2020 · ESMO Open · 29 citations
https://doi.org/10.1136/esmoopen-2020-000724
Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)
2023 · ESMO Open · 24 citations
https://doi.org/10.1016/j.esmoop.2023.101192
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top
2025 · Molecules · 13 citations
https://doi.org/10.3390/molecules30122645
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat